Article

#17: Gene Therapy and its Potential in Macular Degeneration

Gene therapy first hit the radar of retinal physicians in 2008, when three independent research groups reported that patients with Leber's congenital amaurosis, a rare genetic retinal disease, had been successfully treated using gene therapy with adeno-associated virus (AAV).

Gene therapy first hit the radar of retinal physicians in 2008, when three independent research groups reported that patients with Leber's congenital amaurosis, a rare genetic retinal disease, had been successfully treated using gene therapy with adeno-associated virus (AAV).

Since then, a host of researchers have begun to explore the potential use of gene therapy in, among other conditions, age-related macular degeneration (AMD). Current research is primarily focused on cutting down the current need for frequent administration of an anti-vascular endothelial growth-factor (VEGF) agent to just a single, subretinal injection.

Gene therapy is a promising area of ongoing research in patients with macular degeneration.

Gene therapy is not, as often misconstrued, limited to the treatment of genetic diseases, but is rather a treatment modality in which genetic material is introduced into cells, either to compensate for an abnormal gene or to make a beneficial protein. Current gene therapy trials in AMD focus on this second area.

A handful of phase I gene therapy trials of VEGF-binding proteins were completed with promising results in small numbers of patients with AMD. However, results from a phase II trial reported in July 2015 of Avalanche Biosciences' AVA-101 in wet AMD have stemmed a bit of the momentum. In that trial, while the primary endpoint of safety (as determined by number of complications at 1 year vs. placebo) was met, results from secondary efficacy goals such as visual acuity and reducing retinal thickness were not as impressive. Based on these results, a planned phase IIB trial was halted.

Nonetheless, several additional phase II trials testing other gene therapy technologies have recently opened to enrollment. Two of these trials are focusing on cell therapy for atrophic AMD while a third is focused on patients with geographic atrophy secondary to AMD.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.